These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26122624)

  • 1. Effects of fluoroquinolone restriction (from 2007 to 2012) on resistance in Enterobacteriaceae: interrupted time-series analysis.
    Sarma JB; Marshall B; Cleeve V; Tate D; Oswald T; Woolfrey S
    J Hosp Infect; 2015 Sep; 91(1):68-73. PubMed ID: 26122624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis.
    Sarma JB; Marshall B; Cleeve V; Tate D; Oswald T; Woolfrey S
    J Hosp Infect; 2015 Sep; 91(1):74-80. PubMed ID: 26169793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence of qnr genes in clinical Enterobacteriaceae non-susceptible to fluoroquinolone in Poland].
    Piekarska K; Rzeczkowska M; Zacharczuk K; Chróst A; Januszkiewicz A; Bareja E; Olak M; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(3):211-9. PubMed ID: 23285775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].
    Noguera O; Rodríguez JC; López JM; Ruiz M; Royo G
    Rev Esp Quimioter; 2009 Mar; 22(1):30-3. PubMed ID: 19308744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.
    van der Starre WE; van Nieuwkoop C; Paltansing S; van't Wout JW; Groeneveld GH; Becker MJ; Koster T; Wattel-Louis GH; Delfos NM; Ablij HC; Leyten EM; Blom JW; van Dissel JT
    J Antimicrob Chemother; 2011 Mar; 66(3):650-6. PubMed ID: 21123286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase.
    Morfín-Otero R; Mendoza-Olazarán S; Silva-Sánchez J; Rodríguez-Noriega E; Laca-Díaz J; Tinoco-Carrillo P; Petersen L; López P; Reyna-Flores F; Alcantar-Curiel D; Garza-Ramos U; Garza-González E
    Microb Drug Resist; 2013 Oct; 19(5):378-83. PubMed ID: 23725513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital.
    Gibold L; Robin F; Tan RN; Delmas J; Bonnet R
    Clin Microbiol Infect; 2014 Jan; 20(1):O20-6. PubMed ID: 23927626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
    Muratani T; Matsumoto T
    Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
    Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
    Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis.
    Muro S; Garza-González E; Camacho-Ortiz A; González GM; Llaca-Díaz JM; Bosques F; Rositas F
    Chemotherapy; 2012; 58(3):217-24. PubMed ID: 22814216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Occurrence of alert pathogens in hospital environment. Part I. ESBL-producing enterobacteriaceae strains].
    Paluchowska P; Skałkowska M; Spelak A; Budak A
    Med Dosw Mikrobiol; 2012; 64(1):35-43. PubMed ID: 22808728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States.
    Bhusal Y; Mihu CN; Tarrand JJ; Rolston KV
    Chemotherapy; 2011; 57(4):335-8. PubMed ID: 21912115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.
    Yokota S; Sato T; Okubo T; Ohkoshi Y; Okabayashi T; Kuwahara O; Tamura Y; Fujii N
    Chemotherapy; 2012; 58(1):52-9. PubMed ID: 22343392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristic of fluoroquinolone resistant clinical isolates of K. pneumoniae, P. mirabilis and E. coli producing ESBL and AmpC beta-lactamases].
    Rzeczkowska M; Piekarska K; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(4):285-95. PubMed ID: 23484420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance.
    Hansen DS; Schumacher H; Hansen F; Stegger M; Hertz FB; Schønning K; Justesen US; Frimodt-Møller N;
    Scand J Infect Dis; 2012 Mar; 44(3):174-81. PubMed ID: 22364227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.